Expert Ratings for Charles River
Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings:
Credit Suisse Initiates Coverage On Charles River with Outperform Rating, Announces Price Target of $285
Credit Suisse analyst Katie Tryhane initiates coverage on Charles River (NYSE:CRL) with a Outperform rating and announces Price Target of $285.
Charles River Laboratories Expands Contract Vivarium Space On West Coast
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the addition of five Charles River Accelerator and Development Lab (CRADL™) locations in California and Washington. CRADL provides flexible,
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading.
Wells Fargo Maintains Overweight on Charles River, Lowers Price Target to $300
Wells Fargo analyst Timothy Daley maintains Charles River (NYSE:CRL) with a Overweight and lowers the price target from $325 to $300.
AMD, SolarEdge Technologies And Some Other Big Stocks Moving Lower On Wednesday
Rocky Brands, Inc. (NASDAQ: RCKY) dipped 21.6% to $26.62 after the company reported worse-than-expected Q2 EPS results.
‘I’m Going To Have To Say Avoid It’: Jim Cramer Urges Waiting Before Buying This Tech Stock
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Charles River Laboratories International Inc (NYSE: CRL).
Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
Program aimed to deliver early-stage clinical supply of plasmid DNA for drug substance manufacturing
WILMINGTON, Mass. & GHENT, Belgium--(BUSINESS WIRE)-- Charles River Laboratories International, Inc.
